Sohini Das

India's overall MedTech opportunity could expand more than fourfold to $83-89 billion by 2035, driven by rising domestic demand, exports and contract manufacturing

NephroPlus said overseas markets now contribute nearly 42 per cent of revenue as the dialysis provider expands globally through acquisitions, PPP projects and clinic additions

Listen to This Article The Competition Commission of India (CCI) has declined to fully endorse findings by its investigative arm in a closely

Rising fuel-price concerns are pushing more consumers to evaluate total ownership costs, even as charging, resale and battery-life worries continue to weigh on EV adoption

Indian pharmaceutical companies are investing in specialty drugs, biosimilars and local manufacturing in the US despite a near 10 per cent fall in exports in FY26

Rating agency Crisil has warned that a prolonged West Asia conflict could significantly squeeze India Inc's profitability in FY27, even as strong balance sheets are expected to cushion broader credit risks.

Firms diversify sourcing, redraw playbook, increase prices to tide over crisis

Boston-headquartered MedTherapy Biotech is expanding its India manufacturing footprint while preparing clinical trials for a lymphoma-focused CAR-T therapy with Cipla

The team put together by the firm's founder may be just what the next decade demands

Nearly three in 10 luxury vehicles sold in India are sedans, with Audi, BMW and Mercedes-Benz each deriving about 40 per cent of India sales from the body style